Clinical Trial Update: A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy [Phase 1]

View source ↗

Summary

The trial investigating maintenance multipeptide vaccine S-588210 in unresectable malignant pleural mesothelioma after first-line chemotherapy has been withdraw…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• S-588210

Snippet

Sponsor: University of Chicago | Conditions: Malignant Pleural Mesothelioma (MPM) | Phase 1 | Status: WITHDRAWN